Cannabinoid Biosciences, Inc.
June 30, 2019
INDEX - Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018 | F-2 |
|
|
Condensed Consolidated Statements of Operations for the six months ended June 30, 2019 and 2018 (unaudited) | F-3 |
|
|
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the six months ended June 30, 2019 (unaudited) | F-4 |
|
|
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018 (unaudited) | F-5 |
|
|
Notes to the Condensed Consolidated Financial Statements (unaudited) | F-7 |
1
CANNABINOID BIOSCIENCES, INC.
(A Development Stage Company)
BALANCE SHEET
June 30, 2019 | December 31, 2018 | ||||||||
(Unaudited) | |||||||||
|
| ASSETS |
|
|
|
|
|
| |
Cash and cash equivalents |
|
|
| $ 18,442 |
| $ 1,393 | |||
|
| ||||||||
Total Current Assets |
|
|
| $ 18,442 |
| $ 1,393 | |||
Fixed Assets |
|
|
| $ 4,200 |
| $ - | |||
| Total assets |
|
|
| $ 22,642 |
| $ 1,393 | ||
LIABILITIES AND STOCKHOLDERS' DEFICIT |
|
|
|
| |||||
Liabilities: |
|
|
|
|
|
|
|
| |
Current liabilities |
|
|
| $ 2,400 |
| $ 2,400 | |||
Long-term liabilities |
|
|
| $ 4,934 |
| $ 9,038 | |||
|
| ||||||||
Total liabilities |
|
|
|
| 7,334 |
| 11,438 | ||
|
|
|
|
|
|
|
|
| |
Stockholders' deficit: | |||||||||
|
|
|
|
|
|
|
|
| |
Common stock ($0.0001 par value) | 1,971 | 1,670 | |||||||
1,000,000,000 shares authorized, no par | �� |
|
| ||||||
19,706,253 issued and outstanding on 06/30/2019, and | |||||||||
16,700,000 issued and outstanding on 12/31/2018 respectively. |
|
|
| ||||||
Additional Paid-in Capital |
|
|
| 117,459 |
| 25,230 | |||
Accumulated Deficits | (104,122) | (36,945) | |||||||
|
|
|
|
|
|
|
|
| |
Total stockholders' equity | 15,308 | (10,045) | |||||||
|
|
|
|
|
|
|
|
| |
Total liabilities and stockholders' equity | $ 22,642 | $ 1,393 | |||||||
The accompanying notes are an integral part of these financial statements | |||||||||
2
CANNABINOID BIOSCIENCES, INC. |
| ||||||||||
(A Development Stage Company) |
| ||||||||||
Statement of Operations |
| ||||||||||
(Unaudited) |
| ||||||||||
| |||||||||||
Six Months Ended June 30, | From |
| |||||||||
2019 | 2018 |
| |||||||||
REVENUE |
|
|
|
|
|
|
|
|
| ||
Total revenue | $ - | $ - | $ - |
| |||||||
|
|
|
|
|
|
|
|
|
| ||
| |||||||||||
EXPENSES: |
|
|
|
|
|
|
|
|
| ||
| |||||||||||
| Rent expense |
| 15,168 |
| 3,300 |
| 24,928 |
| |||
Telephone expense | 1,459 | 2,059 | 8,198 |
| |||||||
| Other operating expenses | 50,550 |
| - |
| 70,996 |
| ||||
| |||||||||||
| Total operating expenses | 67,177 |
| 5,359 |
| 104,122 |
| ||||
| |||||||||||
NET LOSS FROM OPERATIONS |
| (67,177) |
| (5,359) |
| (104,122) |
| ||||
| |||||||||||
|
|
|
|
|
|
|
|
|
| ||
NET LOSS | $ (67,177) |
| $ (5,359) | $(104,122) |
| ||||||
|
|
|
|
|
|
|
|
|
| ||
Basic and diluted loss per common share | $ (0.00341) |
| $ (0.00045) | $(0.00528) |
| ||||||
| |||||||||||
Weighted average number of common shares outstanding |
| ||||||||||
Basic and diluted | 19,706,253 |
| 12,000,000 | 19,706,253 |
| ||||||
| |||||||||||
| |||||||||||
| |||||||||||
| |||||||||||
The accompanying notes are an integral part of these financial statements | |||||||||||
3
CANNABINOID BIOSCIENCES, INC. | ||||||||||
(A Development Stage Company) | ||||||||||
Statement of Cash Flows | ||||||||||
(Unaudited) | ||||||||||
Six Months Ended June 30, | Cumulative from | |||||||||
2019 | 2018 | |||||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
| ||||
Net Loss |
|
|
|
| (67,177) |
| (5,359) |
| (104,122) | |
Adjustments to reconcile net loss to net cash | ||||||||||
provided/(used) by operating activities: |
|
|
|
|
|
|
| |||
Increase (decrease) in: | ||||||||||
Accounts Payable and other accrued liabilities |
|
|
|
|
| 2,400 | ||||
| Total adjustments |
|
| - |
| - |
| 2,400 | ||
Net cash used by operating activities |
| (67,177) |
| (5,359) |
| (101,722) | ||||
|
|
|
|
|
|
|
|
|
| |
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||||
Proceeds from loans payable |
|
|
| (4,200) |
|
|
| (4,200) | ||
Net cash provided by financing activities | (4,200) | - | (4,200) | |||||||
|
|
|
|
|
|
|
|
|
| |
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||||
Proceeds from loans payable |
|
|
| (4,104) |
| 5,359 |
| 4,934 | ||
Proceeds from shares issued | 92,530 | - | 119,430 | |||||||
|
|
|
|
|
|
|
|
|
| |
Net cash provided by financing activities | 88,426 | 5,359 | 124,364 | |||||||
|
|
|
|
|
|
|
|
|
| |
Increase in cash |
|
|
| 17,049 |
| - |
| 18,442 | ||
Cash - beginning of period |
|
|
| 1,393 |
| 200 |
| - | ||
Cash - end of period |
|
|
| 18,442 |
| 200 |
| 18,442 | ||
|
|
|
|
| Six Months Ended June 30, |
|
| |||
2019 | 2018 | |||||||||
Supplemental disclosure of cash flow information: |
|
|
|
|
|
| ||||
Cash paid for interest | 163 | - | ||||||||
Non-cash investing and financing activities: |
|
|
|
|
|
| ||||
Cash paid for Furniture and Equipment | 4,200 | - | ||||||||
|
|
|
|
|
|
|
|
|
| |
The accompanying notes are an integral part of these financial statements | ||||||||||
4
CANNABINOID BIOSCIENCES, INC.
(A Development Stage Company)
STATEMENT OF STOCKHOLDERS' EQUITY
For the period from May 6, 2014 (inception) to June 30, 2019
Deficit | ||||||||||||
Accumulated | ||||||||||||
Additional | during | |||||||||||
Common Stock | Paid-in | Development | Stockholder’s | |||||||||
Shares | Amount | Capital | Stage | Deficit | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at May 6, 2014 (Inception) | - | $ - | $ - | $ - | $ - | |||||||
|
|
| �� |
|
|
|
|
|
|
|
|
|
Issuance of common stock at $0.0001 per share | 12,000,000 | 1,200 | 1,200 | |||||||||
Additional Paid-in Capital |
|
|
|
|
| 400 |
|
|
| 400 | ||
Net Loss | (2,593) | (2,593) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2016 | 12,000,000 |
| $ 1,200 | $ 400 | $ (2,593) | $ (993) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock at $0.0001 per share | - | - | - | |||||||||
Additional Paid-in Capital |
|
|
|
|
| 0 |
|
|
| 0 | ||
Net Loss | (4,198) | (4,198) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2017 | 12,000,000 | $ 1,200 | $ 400 | $ (6,791) | $ (5,191) | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock at $0.0001 per share | 4,700,000 | 470 |
| 25,300 | ||||||||
Additional Paid-in Capital |
|
|
|
|
| 24,830 |
|
|
| 0 | ||
Net Loss | (30,154) | (30,154) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2018 | 16,700,000 | $ 1,670 | $ 25,230 | $ (36,945) | $ (10,045) | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock at $0.0001 per share | 3,006,253 | 300.63 |
| 300,63 | ||||||||
Additional Paid-in Capital |
|
|
|
|
| 92,529 |
|
|
| 0 | ||
Net Loss | (67,177) | (67,177) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2019 | 19,706,253 | $ 1,971 | $ 117,759 | $ (104,122) | $ 15,608 |
The accompanying notes are an integral part of these financial statements |
5
CANNABINOID BIOSCIENCES, INC.
NOTES TO FINANCIAL STATEMENTS
For the period from May 6, 2014 (inception) to June 30, 2019
Note 1 - Organization and Basis of Presentation
Organization and Line of Business
Cannabinoid Biosciences, Inc. was formed on May 6, 2014 under the name “CANNABINOID BIOSCIENCES, INC” a “C” corporation formed under the laws of the State of California.
Cannabinoid Biosciences, Inc. (hereinafter the “Company”) has limited operations and is developing a business plan to focus on providing financial products and services to the legal cannabis businesses in California at first then expand to other parts of the United States once the legal environment is conducive for doing so. The company’s business plan focuses on building an array of turnkey solutions for model dispensaries, production facilities, and product, as well as services providing back-office functions to legal-cannabis business.
Basis of Presentation
The accompanying financial statements have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles (“GAAP”) promulgated in the United States of America.
The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements; the Company does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.
The Company adopted the calendar year as its basis of reporting.
Note 2 – Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Cash Equivalents
For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.
Fair Value of Financial Instruments
Financial Accounting Standards Board (“FASB”) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows:
6
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active).
Level 3 - Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.
The carrying amounts reported in the balance sheets approximate their fair value.
Revenue and Cost Recognition
The Company intends to earn revenues through the sale of its app for smartphones. The Company recognizes revenue in accordance with FASB ASC 605, Revenue Recognition, only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the services have been provided, and collectability is assured. No revenues have been earned or recognized as of June 30, 2019. Expenses are recognized as incurred.
Organizational Costs
In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 720, organizational costs, including accounting fees, legal fees, and costs of incorporation, are expensed as incurred.
Income Taxes
The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.
Basic and Diluted Earnings Per Share
Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were no potentially dilutive securities outstanding during the period from May 6, 2014 (inception) to June 30, 2019.
7
Note 3 – Stockholders’ Equity
The Company authorized 1,000,000,000 shares of capital stock with $0.0001 par value per share.
Common Stock
During the period from January 1, 2019 to June 30, 2019 and May 6, 2014 (inception) to June 30, 2019, the Company issued 3,006,253 for $92,530 value and 19,706,253 for $119,430 value respectively.
Note 4 – Going Concern
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any revenues or profits since inception, and has sustained a net loss of $67,177 and $104,122 for the period from January 1, 2019 to June 30, 2019 and May 6, 2014 (inception) to June 30, 2019 respectively. The Company’s ability to continue as a going concern for the next twelve months is dependent upon its ability to generate sufficient cash flows from operations to meet its obligations, which it has not been able to accomplish to date, and its ability to obtain additional capital financing from investors. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Management plans to raise additional equity capital to the Company as necessary to fund expenditures until the Company’s planned principal operations can generate sufficient cash flows to sustain operations. No assurance can be made that these efforts will be successful and sustain the Company for a reasonable period of time.
Note 5 – Related Party Transactions
During the period from January 1, 2019 to June 30, 2019 and May 6, 2014 (inception) to June 30, 2019, the Company paid rent $15,168 and $24,928 respectively to a company that is owned by the Company’s majority stockholder.
Note 6 – Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of June 30, 2019 and December 31, 2018 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. Because of the impacts of the valuation allowance, there was no income tax expense or benefit for the period from May 6, 2014 (inception) to June 30, 2019.
A reconciliation of the differences between the effective and statutory income tax rates for the period ended June 30, 2019 and December 31, 2018:
8
Percent | June 30, 2019 | December 31, 2018 | |||||||||
|
|
| |||||||||
Federal statutory rates |
| 34.00 | % |
| $ | (35,401.60 | ) |
| $ | (12,561.46 | ) |
State income taxes |
| 5.00 | % |
|
| (5,206.12 | ) |
|
| (1,847.27 | ) |
Permanent differences |
| -0.50 | % |
|
| 520.61 |
|
|
| 184.73 |
|
Valuation allowance against net deferred tax assets |
| -38.50 | % |
|
| 40,087.09 |
|
|
| 14,224.00 |
|
Effective rate |
| 0 | % |
| $ | - |
|
| $ | - |
|
At June 30, 2019 and December 31, 2018, the significant components of the deferred tax assets are summarized below:
June 30, 2019 | December 31, 2018 | |||||
Deferred income tax asset |
|
|
|
|
|
|
Net operation loss carryforwards |
| 40,087.09 |
|
| 14,224.00 | |
Total deferred income tax asset |
| 40,087.09 |
|
|
| 14.224.00 |
Less: valuation allowance |
| (40,087.09) |
|
| (14,224.00) | |
Total deferred income tax asset | $ | - |
|
| $ | - |
The valuation allowance increased by $25,863.09 by June 30, 2019 compared to December 31, 2018, as a result of the Company generating additional net operating losses of $67,176.84.
The Company has recorded as of June 30, 2019 and December 31, 2018, a valuation allowance of $40,087.09 and $14,224.00 respectively, as it believes that it is more likely than not that the deferred tax assets will not be realized in future years. Management has based its assessment on the Company’s lack of profitable operating history.
The Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of December 31, 2017 and 2018.
The Company has net operating loss carry-forwards of approximately $40,087.09. Such amounts are subject to IRS code section 382 limitations and expire in 2032.
Note 7 – Commitments and Contingencies
The Company has no real property and do not presently owned any interests in real estate. From inception to December 31, 2017, the Company for $50 per month, was renting a tiny space it uses to keep its records from Goldstein Franklin Inc., its registered services of process agent, as well as controlling shareholder. In January 2018, the Company entered into lease agreement with Poverty Solutions Inc., to lease office space at $550 per month. From November 2019, the rent was increased to $1,250 due to increase in space needed for the company operations. The Company’s executive, administrative and operating offices are located at 3699 Wilshire Blvd., Suite 610, Los Angeles, CA 90010.
9
Management believed that the current facilities are adequate and that any additional suitable space will be available as maybe required.
From time to time, the Company may be involved in certain legal actions and claims arising in the normal course of business. Management is of the opinion that such matters will be resolved without material effect on the Company’s financial condition or results of operations.
Note 8 – Recent Accounting Pronouncements
In June 2014, the FASB issued Accounting Standards Update (ASU) 2014-10 which eliminated the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods beginning after December 15, 2015. Early application is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has early adopted the new standard effective as of the inception date.
In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide such guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. The Company has not elected to early adopt this pronouncement.
Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Note 9 – Subsequent Events
Pursuant to ASC 855-10, the Company has evaluated all events or transactions that occurred from July 1, 2019 to August 12, 2019. The Company did not have any material recognizable subsequent events that required disclosure in these financial statements except for the following:
Extension of Offering
10
On August 12, 2019, the Company’s board of directors elected to extend the outside termination date for the Company’s Regulation A+ offering from August 31, 2019 to July 31 2020. At that time, the Company updated its subscription agreement for the offering to reflect the extended termination date. The updated subscription agreement would be filed as Exhibit to the Company’s Current Report on Form 1-U filed September 11, 2018.
11